Compare Ascendis Pharma A/S (ASND) vs Cronos Group Inc (CRON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Cronos Group Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Cronos Group Inc trades at $2.76 (market cap $1.02B). The key difference: Ascendis Pharma A/S is far larger — about 17.4× Cronos Group Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals.
| ASND | CRON | |
|---|---|---|
Market Cap | $17.74B | $1.02B |
Sector | Health | Health |
52-Week High | $277.18 | $3.27 |
52-Week Low | $163.32 | $1.95 |
Enterprise Value | $18.11B | $200.66M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CRON trades at $2.75, down 1.08% today. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators are neutral. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent Q1 2026 earnings met expectations with $0.01 EPS, and the company expanded its Spinach brand and international footprint.
Outlook is mixed; strong revenue growth and market share gains in Canada and Israel offer upside, but profitability challenges and intense cannabis competition pose risks. Analyst consensus is cautious with 60% hold ratings. Key catalysts include continued international expansion and execution on cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
